[go: up one dir, main page]

SV1998000010A - Combinaciones para diabetes de sulfonilurea-glitazona. - Google Patents

Combinaciones para diabetes de sulfonilurea-glitazona.

Info

Publication number
SV1998000010A
SV1998000010A SV1998000010A SV1998000010A SV1998000010A SV 1998000010 A SV1998000010 A SV 1998000010A SV 1998000010 A SV1998000010 A SV 1998000010A SV 1998000010 A SV1998000010 A SV 1998000010A SV 1998000010 A SV1998000010 A SV 1998000010A
Authority
SV
El Salvador
Prior art keywords
combinations
glitazone
sulfonylurea
diabetes
antidiabetic agent
Prior art date
Application number
SV1998000010A
Other languages
English (en)
Inventor
Randall W Whitcomb
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of SV1998000010A publication Critical patent/SV1998000010A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LAS COMBINACIONES DE UN AGENTE ANTIDIABETICO DE SULFONILUREA Y UN AGENTE AINTIDIABETICO DE GLITAZONA SON DE UTILIDAD PARA TRATAR LA DIABETES MELLITUS Y PARA MEJORAR EL CONTROL GLUCEMICO
SV1998000010A 1997-02-19 1998-01-22 Combinaciones para diabetes de sulfonilurea-glitazona. SV1998000010A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19

Publications (1)

Publication Number Publication Date
SV1998000010A true SV1998000010A (es) 1999-02-02

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1998000010A SV1998000010A (es) 1997-02-19 1998-01-22 Combinaciones para diabetes de sulfonilurea-glitazona.

Country Status (29)

Country Link
US (2) US5859037A (es)
EP (1) EP0957923A1 (es)
JP (1) JP2001512478A (es)
KR (1) KR20000071179A (es)
CN (1) CN1244801A (es)
AR (1) AR011829A1 (es)
AU (1) AU741215B2 (es)
BG (1) BG103671A (es)
BR (1) BR9714505A (es)
CA (1) CA2272478A1 (es)
CZ (1) CZ289299A3 (es)
EA (1) EA199900725A1 (es)
EE (1) EE9900345A (es)
GT (1) GT199800037A (es)
HN (1) HN1997000167A (es)
HU (1) HUP0001528A3 (es)
IL (1) IL130027A (es)
IS (1) IS5058A (es)
NO (1) NO993982D0 (es)
NZ (1) NZ336002A (es)
PA (1) PA8447401A1 (es)
PE (1) PE74399A1 (es)
PL (1) PL335166A1 (es)
SK (1) SK111899A3 (es)
SV (1) SV1998000010A (es)
TR (1) TR199902033T2 (es)
UY (1) UY24893A1 (es)
WO (1) WO1998036755A1 (es)
ZA (1) ZA981343B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
CA2294582C (en) * 1997-06-18 2008-02-12 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and metformin
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
CA2294385C (en) * 1997-06-18 2007-06-05 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
ATE274510T1 (de) 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
JP2003515523A (ja) * 1998-12-24 2003-05-07 メタベイシス・セラピューティクス・インコーポレーテッド 糖尿病治療のためのｆｂｐアーゼ阻害物質とインスリンセンシタイザの組み合わせ
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
AU784108B2 (en) * 1999-03-15 2006-02-02 University Of British Columbia, The Methods and reagents for modulating cholesterol levels
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
TR200401145T4 (tr) * 2000-04-13 2004-07-21 Pfizer Products Inc. Gliburit ve milrinonun sinerjistik etkisi.
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CN100544717C (zh) 2002-09-20 2009-09-30 华生制药公司 含有双胍和噻唑烷二酮衍生物的药物剂型
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
BRPI0414979A (pt) 2003-10-31 2006-11-21 Takeda Pharmaceutical preparação sólida
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
US20090227493A1 (en) * 2005-05-27 2009-09-10 Daiichi Sankyo Company, Limited Combined drug for treating diabetes
EP1943274A2 (en) * 2005-09-08 2008-07-16 Uutech Limited Treatment of diabetes related obesity
CA2623412A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
JP5179363B2 (ja) 2005-12-22 2013-04-10 武田薬品工業株式会社 固形製剤
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
AU2008232937B2 (en) 2007-03-30 2012-09-27 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
CA2707484C (en) 2007-12-04 2021-08-10 Remedy Pharmaceuticals, Inc. Improved formulations and methods for lyophilization and lyophilates provided thereby
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
CA3213470A1 (en) * 2008-12-04 2010-06-10 Chongxi Yu High penetration compositions and their applications
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
ES2525748T3 (es) * 2009-11-13 2014-12-29 Toray Industries, Inc. Agente terapéutico o profiláctico para la diabetes
CN103025334B (zh) 2010-05-24 2016-03-16 澳星医疗私人有限公司 抗糖尿病组合物和方法
KR102423708B1 (ko) 2011-01-19 2022-07-20 프랙틸 헬쓰, 인코포레이티드 조직의 치료를 위한 장치 및 방법
EP2782586A4 (en) * 2011-11-23 2015-07-01 Ozstar Therapeutics Pty Ltd ENHANCED SYNERGIC ANTIDIABETIC COMPOSITIONS
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
KR102086184B1 (ko) 2012-02-27 2020-03-06 프랙틸 래브러토리스 인코포레이티드 조직의 치료를 위한 열 절제 시스템，장치 및 방법
KR102231179B1 (ko) 2012-04-19 2021-03-22 프랙틸 래브러토리스 인코포레이티드 조직 팽창 디바이스들, 시스템들, 및 방법들
WO2014022436A1 (en) 2012-07-30 2014-02-06 Fractyl Laboratories Inc. Electrical energy ablation systems, devices and methods for the treatment of tissue
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
EP3003461B1 (en) 2013-06-04 2019-05-01 Fractyl Laboratories, Inc. Systems and devices for reducing the luminal surface area of the gastrointestinal tract
WO2015038973A1 (en) 2013-09-12 2015-03-19 Fractyl Laboratories, Inc. Systems, methods and devices for treatment of target tissue
JP6603660B2 (ja) 2013-11-22 2019-11-06 フラクティル ラボラトリーズ インコーポレイテッド 消化管における治療制約の生成のためのシステム、デバイスおよび方法
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
WO2016011269A1 (en) * 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
CN114805531A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
US12403138B2 (en) * 2019-11-22 2025-09-02 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
IL294671A (en) 2020-01-15 2022-09-01 Fractyl Health Inc Automated tissue handling devices, systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU706628B2 (en) * 1995-07-03 1999-06-17 Sankyo Company Limited Treatment of arteriosclerosis and xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
CA2272478A1 (en) 1998-08-27
KR20000071179A (ko) 2000-11-25
EA199900725A1 (ru) 2000-04-24
AU741215B2 (en) 2001-11-29
NZ336002A (en) 2002-03-28
EE9900345A (et) 2000-02-15
ZA981343B (en) 1998-11-16
TR199902033T2 (xx) 2000-02-21
CZ289299A3 (cs) 1999-11-17
AU5590898A (en) 1998-09-09
NO993982L (no) 1999-08-18
CN1244801A (zh) 2000-02-16
SK111899A3 (en) 2000-09-12
JP2001512478A (ja) 2001-08-21
EP0957923A1 (en) 1999-11-24
HUP0001528A3 (en) 2000-12-28
IL130027A0 (en) 2000-02-29
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
IL130027A (en) 2005-09-25
PL335166A1 (en) 2000-04-10
UY24893A1 (es) 1998-07-10
WO1998036755A1 (en) 1998-08-27
US5972973A (en) 1999-10-26
US5859037A (en) 1999-01-12
PE74399A1 (es) 1999-08-20
PA8447401A1 (es) 2001-12-14
HN1997000167A (es) 1999-02-09
IS5058A (is) 1999-05-27
NO993982D0 (no) 1999-08-18
AR011829A1 (es) 2000-09-13
BR9714505A (pt) 2000-03-21
BG103671A (en) 2000-04-28

Similar Documents

Publication Publication Date Title
SV1998000010A (es) Combinaciones para diabetes de sulfonilurea-glitazona.
PA8484901A1 (es) Combinaciones para la diabetes
BR9913833A (pt) Método para tratar diabetes, empregando em inibidor de ap2 e combinação
DE69625157D1 (de) Behandlung des typ ii-deabetes mellitus mit amylinagonisten
DE59811840D1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
BR9204191A (pt) Composicao de isca e processo para controlar populacoes de besouro diabroticine,e isca
AR038437A1 (es) Tintura permanente del cabello en dos pasos
DE69015024D1 (de) Unter Feldeffekt-Emission arbeitende Schaltanordnung und deren Herstellungsverfahren.
BR9707588A (pt) Agente terapeutico para diabetes
ES2058272T3 (es) Fluoxetina util para el tratamiento de la diabetes.
ES2110661T3 (es) Polipropilenos elastomeros modificados.
ES2136724T3 (es) Emulsion liofilizada, que contiene una sustancia activa.
EA200000140A1 (ru) Способ лечения диабета тиазолидиндионом, средством, усиливающим секрецию инсулина, и ингибитором альфа-глюкозидазы
ES2152315T3 (es) Xamoneline tartrato.
ECSP982417A (es) Combinaciones para diabetes de sulfonilurea glitazona
FI906322A7 (fi) Kudosplasminogeeniaktivaattorianalogit, joilla on parantunut aktiivisu us
ECSP993207A (es) Combinaciones para la diabetes
UA41246C2 (uk) Похідні мільбеміцину, що мають пестицидну активність, спосіб лікування ендо- та ектопаразитних інфекцій, спосіб боротьби з комахами та кліщами
BR0013437A (pt) Método para tratamento de infestação do corpo por insetos
DE68914434D1 (de) Doppelzylinder bioreaktor.
AR240479A1 (es) Un agente de curtido de cueros y el procedimiento para curtir.
ES2025117B3 (es) Un derivado de propanona opticamente activo y proceso para producir el mismo y su aplicacion.
DE69323215D1 (de) Rückkopplungsschleife für Aktivhandsteuerknüpppel
ECSP993146A (es) Metodo de tratameinto para la diabetes empleando un inhibidor ap2 y su combinacion

Legal Events

Date Code Title Description
FG Grant